Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. Get access to the ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally ...

Eli Lilly's note offering has received a rating of Aa3 from Moody's (NYSE:MCO) and A+ from S&P, both with a stable outlook. The joint book-running managers for this offering include Barclays (LON ...

Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook ...

Eli Lilly is ramping up its campaign against imitations of its blockbuster appetite-suppressing drugs, seeking to put an end to a regulatory designation that has allowed cheaper, off-brand ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

That makes Eli Lilly a buy in my book. The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of ...